Equities Analysts Set Expectations for ELDN Q1 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has recently come under the spotlight as stock analysts from Leerink Partners shared their predictions for the company's Q1 2025 earnings. In a report released on March 23rd, analyst T. Smith projected an earnings per share (EPS) of ($0.28) for the quarter.

For context, the consensus estimate for Eledon Pharmaceuticals' earnings for the entire year stands at ($0.81) per share. In addition to the quarterly forecasts, Leerink Partners has also laid out their expectations for subsequent quarters, anticipating Q2 2025 earnings of ($0.29) EPS, Q3 2025 at ($0.30) EPS, and Q4 2025 at ($0.29) EPS.

Recent Earnings Results

On March 20th, Eledon Pharmaceuticals announced its latest quarterly earnings, revealing an EPS of ($0.64). This figure fell short of analysts' expectations, which had predicted an EPS of ($0.32), marking a difference of ($0.32). In the same period from the previous year, Eledon reported a significantly higher loss of ($1.00) EPS.

Analyst Coverage and Ratings

In other developments, Guggenheim began coverage of Eledon Pharmaceuticals on January 28th, rating the stock as a "buy" and setting a target price of $9.00.

Current Stock Performance

As of Tuesday, Eledon Pharmaceuticals shares opened at $3.61, showing a 2.8% increase. Over the past year, the stock has fluctuated between a low of $1.52 and a high of $5.54. The company's market capitalization is approximately $215.66 million, with a price-to-earnings ratio of -1.80, and a beta of 0.80. Currently, the 50-day simple moving average is $4.16, while the 200-day average stands at $3.88.

Institutional Investment Activity

Recent activity among major investors indicates a growing interest in Eledon Pharmaceuticals. Tower Research Capital LLC (TRC) significantly increased its holdings by 418.5% in the fourth quarter. TRC now owns 7,944 shares, valued at approximately $33,000 after acquiring an additional 6,412 shares during this period. Renaissance Technologies LLC also increased its holdings in the same quarter by 8.3%, now owning 147,173 shares valued at about $606,000 following the purchase of 11,300 additional shares. Other investors, such as Alpine Global Management LLC, Charles Schwab Investment Management Inc., and Schonfeld Strategic Advisors LLC, have also boosted their stakes in Eledon Pharmaceuticals. Currently, institutional investors hold a total of 56.77% of the company’s stock.

Company Overview

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology firm focused on developing therapies aimed at protecting transplanted organs and preventing rejection. The company's research also targets treatments for amyotrophic lateral sclerosis (ALS) by leveraging its expertise in immunology, specifically in the CD40 Ligand (CD40L) pathway.

Conclusion

With analysts providing their earnings expectations and institutional interest rising, Eledon Pharmaceuticals continues to navigate a challenging yet promising landscape in the biotech sector.

Eledon, Earnings, Stock